Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Eur Acad Dermatol Venereol ; 36(8): 1292-1299, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1807159

ABSTRACT

BACKGROUND: Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. OBJECTIVES: A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from ≥12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined. METHODS: Data of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. RESULTS: One hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. CONCLUSIONS: Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era.


Subject(s)
COVID-19 , Dermatitis, Atopic , Eczema , Antibodies, Monoclonal, Humanized , COVID-19/drug therapy , Dermatitis, Atopic/drug therapy , Double-Blind Method , Humans , Pandemics , Prospective Studies , Pruritus , SARS-CoV-2 , Severity of Illness Index , Treatment Outcome
2.
Tema-Journal of Land Use Mobility and Environment ; 14(3):343-366, 2021.
Article in English | Web of Science | ID: covidwho-1630800

ABSTRACT

Mobility scooters have evolved up to modem cabin versions and to application of still futuristic solutions in the automotive sector: they could even be a resource for individual mobility in the Covid-19 era, but in Italy they seem unable to establish, mainly because of lacking and approximate legislation. Article 46 of the Italian Highway Code generically delegates the definition of "machines for disabled persons" (not considered vehicles) to "current Community provisions", but the explanatory note of heading 8713 of EU Combined Nomenclature of goods and EU Regulations 718/2009 and 2021/1367 equate mobility scooters to motor vehicles: as such they are an unknown entity for the Highway Code, therefore they should be considered unregulated atypical vehicles, which are forbidden in public areas. We propose the classification of mobility scooters as "motor vehicles" for both able and disabled persons and a specific regulation of their characteristics and circulation. Our legislative proposal could be useful even outside Italy, since some disputes at the European and National Courts and the absence of mobility scooters among the three-wheel vehicles and quadricycles categorized by EU Regulation 168/2013 are a symptom that they are still a controversial topic even abroad and need a clear-cut national and international legislation.

SELECTION OF CITATIONS
SEARCH DETAIL